Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 9, 2022

Primary Completion Date

June 3, 2026

Study Completion Date

June 3, 2026

Conditions

Advanced Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm

Interventions

DRUG

Cabozantinib

Given PO

DRUG

Pamiparib

Given PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER